Evolution of Lipid Therapy: Combination Therapy and the Changing Landscape of CV Risk Reduction CME

Christie M. Ballantyne, MDAuthor Information and Disclosures

Release Date: October 3, 2008; Valid for credit through October 3, 2009

Credits Available
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Estimated time to complete activity: 45 minutes.

This CME activity is based on a series of webinar meetings titled "Evolution of Lipid Therapy: Combination Therapy and the Changing Landscape of CV Risk Reduction."

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Educational Concepts in Medicine
Abbott
Learning Objectives
After completing this activity, the participant should be better able to:
  1. Describe how the concept of "residual risk" applies to patients with mixed dyslipidemia; that most patients require therapy that targets more than one lipid parameter
  2. Explain how HDL-C is an independent risk factor for CHD
  3. Describe important barriers to optimal risk reduction with currently available treatments
  4. Describe the benefits of fixed-dose combination therapy for mixed dyslipidemia
Authors and Disclosures

Christie M. Ballantyne, MD
Disclosure: Dr. Ballantyne: Consultant: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Atherogenics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals; Pfizer Inc.; Sanofi-Synthelabo; Schering-Plough; Takeda Pharmaceuticals. Speakers Bureau: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Pfizer Inc.; Reliant Pharmaceuticals, Inc.; Schering-Plough. Contracted Research: Abbott Laboratories; ActivBiotics; Gene Logic Inc.; GlaxoSmithKline; Integrated Therapeutics Group, Inc.; Merck and Co., Inc.; Pfizer Inc.; Sanofi-Synthelabo; Schering-Plough; Takeda Pharmaceuticals.


Terry A. Jacobson, MD
Disclosure: Dr. Jacobson: Consulting Fees (e.g., advisory boards): Abbott, AstraZeneca, Merck, Pfizer, Schering-Plough, Reliant. Fees for Non-CME Services Received Directly from a Commercial Interest or their agents (e.g., speakers’ bureaus): Abbott, AstraZeneca, Merck, Pfizer, Schering-Plough, Reliant.


PIM Clinical Reviewers: Jan Hixon, RN; Trace Hutchison, PharmD; and Linda Graham, RN
Disclosure: The planners and managers have no real or apparent conflicts of interest to report.
 
Postgraduate Institute for Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine (PIM) designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Estimated Time to Complete Activity: 45 minutes

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.